Eculizumab’s Complement Blockade Fell Short of Proving Added AMR Protection
Peri-transplant eculizumab has a strong biological rationale in kidney transplantation, but the clinical record stops short of proving an incremental benefit against antibody-mediated rejection in high-immunologic-risk recipients. This systematic review pulled together randomized data, historical comparisons, single-arm cohorts, and case-based reports across HLA-sensitized, donor-specific antibody positive, and ABO-incompatible settings, then separated the evidence by study design rather than flattening it into one pooled estimate. That approach matters because the background regimens were not interchangeable: plasma exchange, immunoadsorption, intravenous immunoglobulin, B-cell–targeted therapy, and maintenance immunosuppression all varied across reports and eras.
The terminal complement pathway remains an appealing target. Pre-existing donor-specific antibodies can activate the classical complement cascade on the graft endothelium, leading to C5 cleavage, C5a generation, and assembly of the C5b-9 membrane attack complex, which amplifies endothelial injury and inflammatory recruitment. Eculizumab interrupts that final step, but it does not remove antibodies, suppress upstream complement activation, or neutralize complement-independent antibody effects. In practice, it can only cover one segment of a much larger immune attack.
Randomized Evidence Did Not Show Fewer Biopsy-Confirmed AMR Events
The clearest signal came from the only randomized trial in the review. Centrally confirmed AMR occurred in 5 of 51 recipients in the eculizumab arm and 5 of 51 recipients in the standard-desensitization arm, producing a risk ratio of 1.00 with a wide confidence interval. No separation emerged between the groups on that endpoint. For a drug intended to blunt early terminal complement injury, the absence of a measurable advantage in the controlled trial is hard to ignore.
A much older historical comparison looked more favorable on paper, with AMR in 2 of 26 recipients versus 21 of 51 in the comparison group, but the review makes clear why that difference cannot be treated as clean evidence of drug effect. Treatment era changed, post-transplant plasma exchange differed, and clinical management evolved at the same time. The biology may be plausible; the comparison was not experimentally protected from confounding.
Single-Arm Cohorts Showed Early Events Despite Prophylaxis
A single-arm study of 80 recipients still recorded three AMR events by week 9. Early post-transplant rejection in this context is exactly where terminal complement blockade should have its strongest theoretical effect, because reperfusion exposes the graft to circulating antibody almost immediately. Yet the presence of early events despite prophylaxis suggests that complement blockade alone cannot reliably overcome persistent humoral risk when the upstream antibody burden remains high or rebounds after surgery.
Longer follow-up added another sobering layer. Across extended observations, the review found no consistent graft-survival or kidney-function advantage. Persistent donor-specific antibodies and chronic microvascular injury remained evident in long-term follow-up. In other words, even when early injury appeared dampened in some cohorts, the immune process did not vanish; it continued to mark the graft over time.
Background Therapy Likely Determined More Than the Drug Itself
The review repeatedly returns to a central clinical reality: the effect of eculizumab cannot be separated from the rest of the desensitization package unless the background therapy is standardized. Plasma exchange reduces circulating antibody, but antibody rebound can occur. IVIG and B-cell–directed therapies modify humoral immunity in different ways. Maintenance immunosuppression and rescue thresholds also shape whether a biopsy becomes a rejected graft or a manageable episode. When those elements shift across studies, the contribution of terminal complement blockade becomes difficult to isolate.
This is especially important in settings such as ABO-incompatible transplantation and HLA-incompatible living-donor transplantation, where the baseline immunologic risk is already high and the co-interventions are often intensive. Small case series and mixed-indication reports can show successful transplantation under a particular protocol, but they cannot establish that eculizumab was the decisive protective element. They mainly show feasibility inside a larger treatment bundle.
Safety Reporting Leaves Open Infection Concerns and Long-Term Tradeoffs
Terminal complement inhibition carries a biologically obvious safety concern: impaired defense against encapsulated organisms. The review calls for infection surveillance in future trials, and that need is not academic. If a prophylactic strategy suppresses one immune pathway at the expense of infectious risk, the balance only makes sense when both efficacy and safety are measured for long enough to capture delayed harm as well as early rejection.
The evidence base also leaves important pathology questions unresolved. Chronic microvascular injury and donor-specific antibodies persisted in long-term follow-up, suggesting that early complement blockade does not necessarily prevent the downstream remodeling that eventually threatens graft durability. A therapy that changes the first weeks after transplantation may still fail to alter the longer arc of chronic alloimmune injury.
What the Review Can and Cannot Support
The review supports a narrower conclusion than many clinicians may want: eculizumab can provide terminal complement blockade within selected combination prophylaxis, but randomized evidence does not establish an added reduction in AMR. The drug remains biologically coherent, especially when administered before and after reperfusion in a recipient with preformed antibodies, yet the available comparative data do not prove that it improves the outcomes that matter most — biopsy-confirmed rejection, graft survival, kidney function, or chronic injury.
For future trials, the design requirements are unusually strict. Background therapy must be standardized, rescue criteria defined in advance, and long-term graft outcomes followed beyond the early postoperative window. Infection monitoring also needs to be built in, because complement blockade changes host defense as well as graft biology. Without those guardrails, the field will keep producing studies that are difficult to compare and even harder to interpret.
The evidence base is registered, broad, and clinically relevant, but it remains fragmented by design, scenario, and co-intervention. The current record does not justify treating peri-transplant eculizumab as a proven incremental shield against antibody-mediated rejection in high-risk kidney transplantation.